Abstract
Background Processed meat and alcohol have been consistently associated with breast cancer risk, but evidence for their effects in women with different genetic susceptibility of breast cancer is scarce, and little is known about their interactions.
Methods We analyzed data from 260,779 female participants in the UK Biobank. Multivariable adjusted Cox proportional hazards models were used to estimate hazard ratios (HR) and 95% confidence intervals (CI) for associations between processed meat and breast cancer risk. We further assessed its interaction with alcohol intake and polygenic risk score (PRS) for breast cancer.
Results Processed meat intake more than once a week was positively associated with risk of breast cancer, especially in women took alcohol ≥1/d (HR=1.50, 95% CI=1.17-1.93), and in women who usually took alcohol together with meals (HR=1.70, 95% CI=1.21-2.39, P for interaction=0.048). The association between processed meat and breast cancer did not differ by menopausal status. When further stratified by PRS, processed meat more than once a week intake was associated with risk of breast cancer (HR=1.17, 95% CI=1.02-1.35) in women with the highest quantile of PRS, and additive interaction was found between them.
Conclusions Processed meat was associated with risk of breast cancer in women, and the effect was stronger in those who took alcohol together with the meal and with high PRS of breast cancer, suggesting the focus of future preventive measures on these women.
Funding This work was supported by the Natural Science Foundation of Fujian Province [grant no: 2021J01721], the Startup Fund for High-level Talents of Fujian Medical University [grant no: XRCZX2020007], Startup Fund for Scientific Research, Fujian Medical University [grant no: 2019QH1002] and Laboratory Construction Program of Fujian Medical University [grant no: 1100160208].
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
This is not a clinical trial
Funding Statement
This work was supported by the Natural Science Foundation of Fujian Province [grant no: 2021J01721], the Startup Fund for High-level Talents of Fujian Medical University [grant no: XRCZX2020007], Startup Fund for Scientific Research, Fujian Medical University [grant no: 2019QH1002] and Laboratory Construction Program of Fujian Medical University [grant no: 1100160208]. The funders had no role in the study design, data collection, analyses, data interpretation, writing the manuscript, or in the decision to submit the manuscript for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The UK Biobank was approved by the National Information Governance Board for Health and Social Care and the National Health Service North West Centre for Research Ethics Committee (Ref: 11/NW/0382, 17 June 2011).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.